Chronicle Journal: Finance

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Celgene Corp (NQ: CELG)
98.95 USD  +0.28 (+0.28%)
Official Closing Price  /  Updated: 5:30 PM EDT, Sep 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,180,100
Open 98.55
Bid (Size) 98.43 (1)
Ask (Size) 98.95 (10)
Prev. Close 98.67
Today's Range 98.45 - 99.33
52wk Range 58.59 - 99.36
Shares Outstanding 706,839,191
Dividend Yield N/A
Performance
YTD
+48.48%
+48.48%
1 Month
+3.87%
+3.87%
3 Month
+0.84%
+0.84%
6 Month
+10.40%
+10.40%
1 Year
+13.24%
+13.24%
Top News
More News
Notable Thursday Option Activity: CL, CELG, BLK
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Colgate-Palmolive Co. (CL), where a total of 13,455 contracts have traded so far, representing... Read More
category Stocks
from Market News Video
Vanguard Mega Cap Growth ETF Experiences Big Outflow
Symbols mentioned in this story: MGK, BMY, BDX, CELG Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''... Read More
category ETFs
from ETF Channel
More News
Read More
Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints
from Business Wire News Releases
Celgene Corp (CELG) Approaches New Downside Target of $98.33
from Comtex SmarTrend® News Briefs
U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers
category companyNews
from Reuters: Company News
Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
from Business Wire News Releases
Could Amgen's Latest Bad News Boost the Chances of More Acquisitions?
category CELG , BMY , Market News , and 1 more.
from Motley Fool
This Biotech Just Flopped On A Test; Why Analysts Remain Bullish
from Investor's Business Daily
Is iShares Nasdaq Biotechnology Index Fund a Buy?
category FBT , AMGN , Market News , and 6 more.
from Motley Fool
Celgene Corp: 52-Week High Recently Eclipsed (CELG)
from Comtex SmarTrend® News Briefs
Better Buy: Celgene vs. Gilead Sciences
category BMY , CELG , Market News , and 1 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]